Cargando…
Hypoxia-Activated Albumin-Binding Exatecan Prodrug for Cancer Therapy
[Image: see text] As an effective drug delivery strategy for traditional antitumor drugs, the stimulus-responsive albumin-based prodrugs are getting more and more attention. These prodrugs only release drugs in specific tumor microenvironments, which can prevent premature release of the drug in the...
Autores principales: | Cheng, Zhiyang, Huang, Ying, Shao, Pingxuan, Wang, Lei, Zhu, Shulei, Yu, Jiahui, Lu, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2021
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8757358/ https://www.ncbi.nlm.nih.gov/pubmed/35036771 http://dx.doi.org/10.1021/acsomega.1c05671 |
Ejemplares similares
-
Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform
por: Conilh, Louise, et al.
Publicado: (2021) -
A Very Long-acting Exatecan and Its Synergism with DNA Damage Response Inhibitors
por: Fontaine, Shaun D., et al.
Publicado: (2023) -
Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy
por: Li, Yue, et al.
Publicado: (2021) -
Bioresponsive albumin-conjugated paclitaxel prodrugs for cancer therapy
por: Yang, Jincheng, et al.
Publicado: (2018) -
A paclitaxel prodrug with bifunctional folate and albumin binding moieties for both passive and active targeted cancer therapy
por: Shan, Lingling, et al.
Publicado: (2018)